Ukranian pharma industry calls for reforms to biosimilars

Ukrainian trade group The Association of Pharmaceutical Research and Development (APRaD) has called for changes to be made to the regulation and implementation of biosimilars in the region.

The APRaD says: “Side-by-side market existence of several biosimilars referring to the same original biologic can create a challenging environment for patients and physicians.”

The group wants each biosimilar to be evaluated on a case-by-case basis during its state registration: “Including evaluation of the unique properties and ingredients of each.”